• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Cardiovascular outcomes are similar for arthritis patients treated with selective and nonselective NSAIDs

byDayton McMillanandShaidah Deghan, MSc. MD
December 29, 2016
in Cardiology, Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients with arthritis treated with celecoxib experienced cardiovascular (CV) outcomes at a rate noninferior to those treated with ibuprofen or naproxen.

2. Celecoxib treated patients experienced adverse gastrointestinal events at a lower rate compared to patients treated with ibuprofen or naproxen.

Evidence Rating: 1 (Excellent)

Study Rundown: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for pain management as they inhibit prostaglandin production. Selective NSAIDs are theorized to reduce gastrointestinal NSAID side effects while being similarly efficacious for pain control compared to nonselective NSAIDs. Previous research suggested selective NSAID use may result in more CV adverse events compared with nonselective NSAID use. This study aimed to assess CV and side effects seen when arthritis patients are treated with selective (celecoxib) or nonselective (ibuprofen or naproxen) NSAIDs and determine if the celecoxib regimen was noninferior to the ibuprofen or naproxen regimens.

A randomized controlled trial was conducted which included patients with arthritis that had CV disease or arthritis patients who were at increased risk of CV disease. Patients were treated with one of the three NSAIDs mentioned and followed to assess for potential side effects. CV side effect rates seen in patients treated with celecoxib were not worse than those of patients treated with ibuprofen or naproxen. Gastrointestinal side effects were observed significantly less in the celecoxib group.

Click to read the study, published today in NEJM

Relevant Reading: Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2

RELATED REPORTS

Diet and exercise is associated with small improvements in knee pain in osteoarthritis

Wellness Check: Nutrition

Carotid and femoral bruits as cardiovascular risk indicators in a middle-aged Finnish population

In-Depth [randomized controlled trial]: From 2006 to 2014, at 926 medical centers in 13 countries, 24 222 patients were enrolled in the study. Patients were assigned to celecoxib, naproxen, or ibuprofen groups in a randomized 1:1:1 fashion. Patients were eligible for the study if they required NSAID treatment for arthritis pain, and had either established CV disease or were at an increased risk for CV disease development. The celecoxib group had 8,072 patients (mean [±SD] daily dose, 209±37 mg), 7,969 patients in the naproxen group (852±103 mg), and 8,040 patients in the ibuprofen group (2045±246 mg). Mean treatment and follow-up duration for all patients was, respectively, 20.3±16.0 and 34.1±13.4 months.

The primary study outcome was death from any CV cause, secondary outcome was occurrence of a major CV event, and additional outcomes measured were gastrointestinal or renal adverse events. An intention-to-treat analysis revealed that the primary outcome occurred in 2.3% of the celecoxib group, 2.5% of the naproxen group, and 2.7% in the ibuprofen group. The HR for celecoxib compared to naproxen was 0.93 (95%CI 0.76-1.13; p < 0.001 for noninferiority). The HR for celecoxib compared to ibuprofen was 0.85 (95%CI 0.70-1.04; p < 0.001 for noninferiority). For secondary outcomes, the HR for celecoxib compared to naproxen was 0.97 (95%CI 0.83-1.12; p = 0.64), and the HR for celecoxib compared to ibuprofen was 0.87 (95%CI, 0.75-1.01; p = 0.06). Serious gastrointestinal events occurred significantly less in the celecoxib group comparted to the ibuprofen (HR 0.65; 95%CI 0.50-0.85; p = 0.002) and naproxen (HR 0.71; 95%CI 0.54-0.93; p = 0.01) groups. Significant renal events occurred significantly less in the celecoxib group compared to the ibuprofen group (HR 0.61; 95%CI 0.44-0.85; p = 0.004).

Image: CC/Wiki

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascular risknsaidsosteoarthritis
Previous Post

Prenatal fish oil supplementation associated with lower risk of asthma in children: The COPSAC trial

Next Post

No significant difference found at 5-year follow-up between bilateral and single CABG: The ART trial

RelatedReports

Physical therapy reduces pain in adults with knee osteoarthritis
Chronic Disease

Diet and exercise is associated with small improvements in knee pain in osteoarthritis

December 26, 2022
Dietary variety linked to greater increase in childhood BMI
Wellness

Wellness Check: Nutrition

December 28, 2022
UTI associated with increased risk of preeclampsia
Cardiology

Carotid and femoral bruits as cardiovascular risk indicators in a middle-aged Finnish population

December 13, 2022
Patient Basics: Ankle Fracture
Chronic Disease

No difference in clinical outcomes between joint replacement and fusion surgeries for ankle osteoarthritis

December 2, 2022
Next Post
PCI not superior to medical therapy alone in stable coronary disease: The COURAGE study

No significant difference found at 5-year follow-up between bilateral and single CABG: The ART trial

Earlier puberty associated with increased risk of depression in girls

Effect of a primary care-based psychological intervention on common mental disorders in Zimbabwe

Diabetes and ischemic heart disease account for highest personal health care spending in U.S.

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options